Search
Search
Examining how the pandemic affects Southwestern Ontario's frontline hospital workers
LONDON, ON - A team from Lawson Health Research Institute will examine the unique personal and professional impacts of the COVID-19 pandemic on frontline hospital workers in Southwestern Ontario. The region’s frontline hospital workers are invited to participate in an online survey to share their experiences during the public health emergency. The goal is to understand impacts unique to our region in order to develop strategies that address the needs of hospital workers.
“It’s crucial to understand the impact of this pandemic on frontline hospital workers who often face difficult decisions, including risking personal safety to care for patients and the community,” explains Dr. Kimia Honarmand, Lawson Adjunct Scientist and Critical Care Physician at London Health Sciences Centre (LHSC). “Experiences are likely to vary across the province and country based on local circumstances. It’s important we hear the unique perspectives of those in our region.”
The team will recruit health care professionals from hospitals across Southwestern Ontario. Participants will be asked to complete one short survey with questions about their perceptions, causes of stress and coping strategies during the pandemic. The team hopes results can be used to identify strategies that address informational, training and support needs.
In addition to worries about personal safety, the team notes that frontline workers are faced with concerns about rapidly evolving information, patient surges and depletion of resources like ventilators and personal protective equipment (PPE). They suspect social media may play a role in compounding these fears.
“Compared with past outbreaks like SARS, today’s digital age provides a wealth of on-demand information and the majority is unverified,” says Dr. Honarmand. “While social media can be a place of solidarity and connection, it can also contribute to the spread of misinformation and fear.”
The researchers also suspect that public health measures like physical distancing, while crucial to controlling the spread of disease, may contribute to a loss of social support systems.
“Taken together, these challenges can lead to stress, anxiety and burnout,” says Carol Young-Ritchie, Executive Vice President, Chief Nursing Officer and Pandemic Incident Management Team Co-Lead at LHSC. “Hearing directly from those on the frontline can help guide hospital administrators and professional organizations in better supporting our people, both during the current pandemic and in future public health emergencies.”
Frontline hospital workers in Southwestern Ontario can learn more and access the survey at https://redcap.lawsonresearch.ca/surveys/?s=E9KKL3CXYE.
-30-
Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world. To learn more, visit www.lawsonresearch.ca.
Senior Media Relations Consultant
Communications & Public Engagement
T: 519-685-8500 ext. 73502
Celine.zadorsky@lhsc.on.ca
Expanded No Fixed Address strategy houses half of those in danger of homelessness
At a community symposium on health care and homelessness attended by over 250 Londoners, a research team from Lawson Health Research Institute announced the results of a nine-month, federally funded project tackling the issue of homelessness from within hospital walls.
The No Fixed Address (NFA) strategy reaches and supports patients during the crucial transitional period when they are being discharged from the hospital and re-integrated into the community. The approach was initially tested with strong success for mental health patients across the city and the second ‘version’ of the project was extended to medical units at London Health Sciences Centre’s University Hospital and Victoria Hospital.
“Many of our patients with lived experience of homelessness were saying that their journey started with a hospital discharge,” explains Dr. Cheryl Forchuk, Assistant Scientific Director at Lawson and NFA project lead. “They were often experiencing major transitions in their lives and then experienced a hospital stay. Normally a relatively short visit, they aren’t able to gather the information and make a plan to be able to leave the hospital with somewhere to stay.”
Through partnerships between service providers and non-profit organizations, the NFA strategy helps prevent homelessness by providing timely and accessible supports to patients who would otherwise be discharged into homelessness. Staff from the Canadian Mental Health Association Middlesex, Salvation Army’s Housing Stability Bank, and Ontario Works in the City of London provided direct, on-site patient access to housing and income support databases
“Lawson’s No Fixed Address research project is the first evaluation anywhere of a strategy that aims to reduce the number of hospital patients being discharged into homelessness,” says Dr. Forchuk.
Over nine months, 74 people experiencing medical health issues accessed the NFA program. Of those, 54 per cent were also experiencing mental health challenges.
All of the study participants were in imminent danger of homelessness. Through the supports provided as part of this research study, half were able to arrange housing before being discharged.
“We were able to help a lot of people, with 50 per cent successfully securing housing,” shares Dr. Forchuk. “With the results and feedback we received, we learned a lot about how we can make the program even better.”
They found that there is a need for the supports to be extended as a transitional program in the community post-discharge, as the length of stay in the medical units tended to be short.
The project’s previous phase, involving acute and tertiary psychiatric care in the London region, prevented homelessness in 95 per cent of cases. “Going into the medical units, we found that people have highly complex needs that often involved mental health challenges.
By simply using the same approach that we did for those in psychiatric care, we helped half of the people find housing. To best serve the needs of everyone, we want to follow them after discharge.”
The team sees a solution in having a housing support worker provide transitional, wrap-around services that follow the person. They would continue to meet and work together after the hospital stay, helping to access community programs.
“This role would be embedded in both the health care system and the homeless serving system, supporting individuals who have complex physical and mental health issues as they are also navigating homeless resources.”
This project is funded by the Government of Canada's Homelessness Partnering Strategy’s (HPS) Innovative Solutions to Homelessness funding stream.
Overview and Numbers
Fast facts on homelessness and health care
- Stable housing after discharge is associated with higher quality of life, reduced substance abuse and fewer hospital admissions.
- Homeless clients are four times more likely to be readmitted to hospital within a month compared to low-income matched controls.
- Hospital care for homeless clients costs an average of $2,559 more per client.
- Finding appropriate housing or avoiding a potential eviction takes time – it is important to start as soon as possible during the discharge process.
Implementation of first phases of No Fixed Address
- Access on the unit to a housing advocate and income support staff.
- The initial intervention was accessed by 219 acute psychiatric clients, as well as 32 clients within a specialized tertiary care psychiatric hospital - only 3 became or remained homeless.
- Expanded to be an immediate wrap-around service with offices set up in the hospital mental health units.
- Staff from the Canadian Mental Health Association Middlesex (CMHA), Ontario Works (OW), and Salvation Army’s Housing Stability Bank (HSB) have on-site access to housing and income support databases.
- Clients can access service by drop-in or appointment.
- Services include assistance for finding housing, financial assistance, such as rent/utilities in arrears or first/last months’ rent for a new home, and access to high quality used furnishings, household supplies and a cleaning service.
Expanded second phase of No Fixed Address
- Program ran from July 2018 to March 2019 (9 months).
- 74 people accessed the program.
- Complex situations with both mental health and physical problems: 100% had medical issues and 54% had mental health issues.
- Lengths of stay were very short.
- People could not attend drop-in due to medical issues, so they relied on referral from staff.
- Although they were all in imminent danger of homelessness, 38 people (50%) were housed as a result of this program.
What were the main housing needs?
- Help finding a place to live
- Money for deposit
- Financial support
- Transportation support
- Help getting benefits
Recommendations and learnings for future models
- Housing support worker needs to be a transitional support since work will be needed after discharge.
- Social work not the only key players (patient care facilitators, nursing staff, etc.).
- The transitional housing support role needs to be well embedded in the homeless serving system, as well as health care.
- People have physical and mental health issues and are also going to be navigating homeless resources.
- Despite the low success rate, many people were housed who would have otherwise been discharged to homelessness.
- We learned a lot about what was needed in an area where there was a knowledge vacuum.
- Future plans involve implementation with improvements to the model.
Exploring mobile software to better support youth mental health
Mental health services are rooted in relationships. When it comes to delivery, and specifically community-based and outpatient services, connection and communication between the individual and care provider need to be the focus.
When we think of youth in particular, technology is a regular form of communication for them.
“Our research team at Lawson is looking at how technology can assist in the delivery of mental health services for youth in a way that still supports the important components of treatment,” says Dr. Cheryl Forchuk, Assistant Scientific Director at Lawson. “In our work with youth, they’ve talked about wanting the technology they are already using integrated into their care.”
In the health care sector, the use of technology needs to be carefully tested and implemented, to ensure it is not only meeting the needs of those using it but also that it complies with the standards for privacy and security.
On February 7, 2019, Lawson Health Research Institute and InputHealth welcomed community members and stakeholders for the announcement of a new health care technology solution that is being researched by Dr. Forchuk and her team, with generous contributions from the provincial government.
TELEPROM-Y is a mobile-based TELEMedicine and Patient-Reported Outcome Measurement Youth study aiming to improve access to specialized services and reduce inpatient mental health admissions for youth. The initiative is one of 11 that received funding from Ontario’s second round of the Health Technologies Fund (HTF), a program of the Ontario Ministry of Health and Long-Term Care administered by Ontario Centres of Excellence.
TELEPROM-Y received $395,109 in provincial funding with $494,630 in matching contributions for a total investment of $889,739.
InputHealth’s CEO Damon Ramsay and Chief Medical Officer Puneet Seth, along with Jennifer Moles from the Ontario Centres of Excellence were on hand with Dr. Cheryl Forchuk to hear more about how the technology and funding will help support youth. Project contributors Woodstock General Hospital and Youth Opportunities Unlimited (Y.O.U.) also attended the announcement.
This project is taking a unique approach to creating connections with youth. Researchers will use an electronic Collaborative Health Record (CHR) developed by InputHealth, an innovative Canadian digital health software company, which allows for secure communication. Patients will have access to virtual visits, prompts and reminders, text or email messages, and educational materials delivered by phone.
InputHealth's Puneet Seth and Damon Ramsay provided a demonstration of the software being used in the study.
Dr. Forchuk explains that “the study is focusing on an important transitional period. The majority of mental illnesses occur between the ages of 16 to 25 years old.” The research team is recruiting participants between these ages who have symptoms of anxiety and/or depression, and are receiving outpatient services from a hospital-based mental health care program at London Health Sciences Centre, St. Joseph’s Health Care London and Woodstock General Hospital, or community-based services from partner organizations.
A key aspect is to assess whether the technology is effective and efficient, while acceptable to both the staff and youth using the app.
“Careful evaluation is essential to make sure we are doing the right things for the people we serve,” adds Dr. Forchuk, who is also the Beryl and Richard Ivey Research Chair in Aging, Mental Health, Rehabilitation and Recovery.
The mobile software will also be evaluated on its ability to improve the ease of access to care; monitor mood and behaviour changes for earlier intervention; enhance information exchange between patient and health care provider; and, support the overall experience for the youth.
Other project contributors include St. Michael’s Hospital Centre for Excellence in Economic Analysis Research, The Forge (McMaster University), Thunder Bay Regional Health Sciences Centre and Western University.
The study extends previous findings from the Youth Mental Health Engagement Network study (Y-MHEN), which developed, delivered and evaluated an interactive web-based personal health record, the Lawson SMART Record (LSR), to assist mental health patients in managing their care and connecting with care providers.
The Health Technologies Fund is a program of the Ontario Ministry of Health and Long-term Care and is administered by the Ontario Centres of Excellence. Program supports the development of made in Ontario health technologies by accelerating evaluating, procurement, adoption and diffusion within the Ontario health system.
Fecal transplants show promise in improving melanoma treatment
LONDON, ON – In a world-first clinical trial published in the journal Nature Medicine, a multi-centre study from Lawson Health Research Institute, the Centre hospitalier de l’Université de Montréal (CHUM) and the Jewish General Hospital (JGH) has found fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma.
Immunotherapy drugs stimulate a person’s immune system to attack and destroy cancer. While they can significantly improve survival outcomes in those with melanoma, they are only effective in 40 to 50 per cent of patients. Preliminary research has suggested that the human microbiome – the diverse collection of microbes in our body – may play a role in whether or not a patient responds.
“In this study, we aimed to improve melanoma patients’ response to immunotherapy by improving the health of their microbiome through fecal transplants,” says Dr. John Lenehan, Medical Oncologist at London Health Sciences Centre’s (LHSC) London Regional Cancer Program (LRCP), Associate Scientist at Lawson and Associate Professor in the Department of Oncology at Western University’s Schulich School of Medicine & Dentistry.
A fecal transplant involves collecting stool from a healthy donor, screening and preparing it in a lab, and transplanting it to the patient. The goal is to transplant the donor’s microbiome so that healthy bacteria will prosper in the patient’s gut.
“The connection between the microbiome, the immune system and cancer treatment is a growing field in science,” explains Dr. Saman Maleki, Scientist at Lawson and LHSC’s LRCP, Assistant Professor in Schulich Medicine’s Departments of Oncology, Pathology and Laboratory Medicine, and Medical Biophysics, and senior investigator on the study. “This study aimed to harness microbes to improve outcomes for patients with melanoma.”
The phase I trial included 20 melanoma patients recruited from LHSC, CHUM and JGH. Patients were administered approximately 40 fecal transplant capsules orally during a single session, one week before they started immunotherapy treatment.
The study found that combining fecal transplants with immunotherapy is safe for patients – which is the primary objective of a phase I trial (also called ‘safety trials’). The study also found 65 per cent of patients who retained the donors’ microbiome had a clinical response to the combination treatment. Five patients experienced adverse events sometimes associated with immunotherapy and had their treatment discontinued.
“We have reached a plateau in treating melanoma with immunotherapy, but the microbiome has the potential to be a paradigm shift,” says Dr. Bertrand Routy, Oncologist and Director of CHUM’s Microbiome Center. “This study puts Canada at the forefront of microbiome research by showing we can safely improve patients’ response to immunotherapy through fecal transplants.”
“These exciting results add to a rapidly growing list of publications suggesting that targeting the microbiome may provide a major advance in the use of immunotherapy for our patients with cancer,” adds Dr. Wilson H. Miller Jr. of the JGH and Professor in the Departments of Medicine and Oncology at McGill University.
The study is unique due to its administration of fecal transplants (from healthy donors) in capsule form to cancer patients – a technique pioneered in London by Dr. Michael Silverman, Lawson Scientist, Chair of Infectious Diseases at Schulich Medicine and Medical Director of the Infectious Disease Care Program at St. Joseph’s Health Care London.
“Our group has been doing fecal transplants for 20 years, initially finding success treating C. difficile infections. This has enabled us to refine our methods and provide an exceptionally high rate of the donor microbes surviving in the recipient’s gut with just a single dose,” says Dr. Silverman. “Our data suggests at least some of the success we are seeing in melanoma patients is related to the efficacy of the capsules."
The team has already started a larger phase II trial involving centres in Ontario and Quebec. Lawson researchers are also studying the potential of fecal transplants in the treatment of other cancers, including renal cell carcinoma, pancreatic cancer and lung cancer, as well as HIV and rheumatoid arthritis.
This research is supported in part through donor funding from London Health Sciences Foundation, Western University, the Lotte and John Hecht Memorial Foundation, the JGH Foundation, Canadian Cancer Society’s Impact Grant program and The Terry Fox Foundation.
-30-
ADDITIONAL DOWNLOADABLE MEDIA
About the CRCHUM
The CHUM Research Centre (CRCHUM) is one of North America’s leading hospital research centres. It strives to improve the health of adults through a continuum of research spanning disciplines such as basic science, clinical research and population health. More than 2,150 people work at the CRCHUM, including nearly 500 researchers and nearly 650 students and postdoctoral fellows. crchum.com
About the Jewish General Hospital
Part of the Integrated Health and Social Services University Network for West-Central Montreal (CIUSSS), the Jewish General Hospital has served patients from Montreal, elsewhere in Quebec, and beyond, since 1934. This McGill University teaching hospital, with approximately 600 beds, is one of the province's largest acute-care hospitals. It admits more than 22,000 patients per year, while handling approximately 578,000 outpatient visits, more than 84,000 emergency visits and more than 3,600 births. Treatment is provided by approximately 800 affiliated doctors, many of whom have teaching appointments at McGill University, as well as more than 300 medical residents per year, together with nursing and a wide range of allied health services.
Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world. To learn more, visit www.lawsonresearch.ca.
Communications Consultant & External Relations
Lawson Health Research Institute
T: 519-685-8500 ext. ext. 64059
C: 226-919-4748
@email
Fecal transplants show promise in improving melanoma treatment
In a world-first clinical trial published in the journal Nature Medicine, a multi-centre study from Lawson Health Research Institute, the Centre hospitalier de l’Université de Montréal (CHUM) and the Jewish General Hospital (JGH) has found fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma.
Immunotherapy drugs stimulate a person’s immune system to attack and destroy cancer. While they can significantly improve survival outcomes in those with melanoma, they are only effective in 40 to 50 per cent of patients. Preliminary research has suggested that the human microbiome – the diverse collection of microbes in our body – may play a role in whether or not a patient responds.
“In this study, we aimed to improve melanoma patients’ response to immunotherapy by improving the health of their microbiome through fecal transplants,” says Dr. John Lenehan, Medical Oncologist at London Health Sciences Centre’s (LHSC) London Regional Cancer Program (LRCP), Associate Scientist at Lawson and Associate Professor in the Department of Oncology at Western University’s Schulich School of Medicine & Dentistry.
A fecal transplant involves collecting stool from a healthy donor, screening and preparing it in a lab, and transplanting it to the patient. The goal is to transplant the donor’s microbiome so that healthy bacteria will prosper in the patient’s gut.
“The connection between the microbiome, the immune system and cancer treatment is a growing field in science,” explains Dr. Saman Maleki, Scientist at Lawson and LHSC’s LRCP, Assistant Professor in Schulich Medicine’s Departments of Oncology, Pathology and Laboratory Medicine, and Medical Biophysics, and senior investigator on the study. “This study aimed to harness microbes to improve outcomes for patients with melanoma.”
The phase I trial included 20 melanoma patients recruited from LHSC, CHUM and Jewish General Hospital. Patients were administered approximately 40 fecal transplant capsules orally during a single session, one week before they started immunotherapy treatment.
The study found that combining fecal transplants with immunotherapy is safe for patients – which is the primary objective of a phase I trial (also called ‘safety trials’). The study also found 65 per cent of patients who retained the donors’ microbiome had a clinical response to the combination treatment. Five patients experienced adverse events sometimes associated with immunotherapy and had their treatment discontinued.
“We have reached a plateau in treating melanoma with immunotherapy, but the microbiome has the potential to be a paradigm shift,” says Dr. Bertrand Routy, Oncologist and Director of CHUM’s Microbiome Center. “This study puts Canada at the forefront of microbiome research by showing we can safely improve patients’ response to immunotherapy through fecal transplants.”
“These exciting results add to a rapidly growing list of publications suggesting that targeting the microbiome may provide a major advance in the use of immunotherapy for our patients with cancer,” adds Dr. Wilson H. Miller Jr. of the JGH and Professor in the Departments of Medicine and Oncology at McGill University.
Previous studies looking at patients receiving immunotherapy who do not respond have found many had an unhealthy microbiome, explains Dr. Lenehan.
“There's a portion of people who don't respond or the treatment just doesn't work,” says Dr. Lenehan. “The hope with the fecal transplant is to make more people respond to treatment.”
These results have also led to a closer examination of the role of the microbiome in regulating how the body responds to disease and how the drugs themselves interact with the microbiome.
“The microbes on and in us - and there's actually a huge amount of those – play a critical role, including modulating some of our immune responses,” explains Dr. Jeremy Burton, Research Chair of Human Microbiome and Probiotics, Scientist at Lawson and St. Joseph’s Health Care London and Associate Professor in the Department of Microbiology and Immunology at Schulich Medicine.
The study is unique due to its administration of fecal transplants (from healthy donors) in capsule form to cancer patients – a technique pioneered in London by Dr. Michael Silverman, Lawson Scientist, Chair of Infectious Diseases at Schulich Medicine and Medical Director of the Infectious Disease Care Program at St. Joseph’s Health Care London.
“Our group has been doing fecal transplants for 20 years, initially finding success treating C. difficile infections. This has enabled us to refine our methods and provide an exceptionally high rate of the donor microbes surviving in the recipient’s gut with just a single dose,” says Dr. Silverman. “Our data suggests at least some of the success we are seeing in melanoma patients is related to the efficacy of the capsules."
The team has already started a larger phase II trial involving centres in Ontario and Quebec. Lawson researchers are also studying the potential of fecal transplants in the treatment of other cancers, including renal cell carcinoma, pancreatic cancer and lung cancer, as well as HIV and rheumatoid arthritis.
This work is not possible without poop donors, and there is a critical need for more. Donors must be between the ages of 18 to 50 and reside in the London, Ont. area. To learn more about eligibility and donating, call the 519 646-6100, ext. 61726 or email Dr. Seema Nair Parvathy, Research Scientist, at SeemaNair.Parvathy@sjhc.london.on.ca.
This research is supported in part through donor funding from London Health Sciences Foundation, Western University, the Lotte and John Hecht Memorial Foundation, the JGH Foundation, Canadian Cancer Society’s Impact Grant program and The Terry Fox Foundation.